Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor

Immune checkpoint inhibitors have shown anti-tumour activity in cancers such as melanoma, renal cell carcinoma, non-small-cell lung cancer, urothelial carcinoma, colorectal cancer, and Hodgkin’s lymphoma. Though immune checkpoint inhibitors have revolutionized the treatment and prognosis of some adv...

ver descrição completa

Detalhes bibliográficos
Autor principal: Rocha,Marta (author)
Outros Autores: Sousa,João Correia de (author), Salgado,Marta (author), Araújo,António (author), Pedroto,Isabel (author)
Formato: article
Idioma:eng
Publicado em: 2019
Assuntos:
Immune checkpoint inhibitor
Immune-related adverse event
Colitis
Diarrhoea
Texto completo:http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452019000400007
País:Portugal
Oai:oai:scielo:S2341-45452019000400007

Texto Completo

http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452019000400007

Registos relacionados